喘患者过敏性鼻炎的药物治疗管理
Ludger Klimek1, Pascal Werminghaus2, Ingrid Casper1
1Center for Rhinology and Allergology Wiesbaden, Wiesbaden, Germany.
Expert opinion on pharmacotherapy
|January 28, 2024
概括
过敏性鼻炎 (AR) 在喘患者中很常见,并且往往未得到充分治疗. 正如指南所建议的,诊断和治疗AR可以改善喘控制,并减少医疗保健的使用.
科学领域:
- 肺部病理学 肺部病理学
- 过敏学 过敏学
- 临床医学 临床医学
背景情况:
- 高达90%的喘患者患有并发性过敏性鼻炎 (AR).
- 在喘患者中,AR经常被诊断不足和治疗不足.
- 未经治疗的AR会对喘管理和医疗保健利用产生负面影响.
研究的目的:
- 审查有关过敏性鼻炎作为喘的并发症和危险因素的文献.
- 强调在喘患者中诊断和治疗AR的重要性.
主要方法:
- 进行了非系统的文献搜索.
- 审查了国际出版物,医学数据库,指南和在线资源.
主要成果:
- 证据证实了在喘患者中诊断和治疗AR的必要性.
- AR增加了喘发育的风险,并加剧了现有的喘.
- 早期AR治疗可以降低喘风险,药物需求和症状严重程度.
结论:
- 对AR的诊断和治疗对于有效的喘管理至关重要.
- 过敏原特异性免疫疗法和其他AR治疗改善了喘的结果.
- 指南建议综合管理AR和喘.
相关概念视频
Asthma: Pathogenesis and Management
403
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
298
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Leukotriene Modifiers
300
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
300


